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Abstract
Background: In humans, imaging of tumors provides rapid, accurate assessment of tumor growth and location. In
laboratory animals, however, the imaging of spontaneously occurring tumors continues to pose many technical and
logistical problems. Recently a mouse model was generated in which a chimeric protein consisting of HIF-1a oxygen-
dependent degradation domain (ODD) fused to luciferase was ubiquitously expressed in all tissues. Hypoxic stress leads to
the accumulation of ODD-luciferase in the tissues of this mouse model which can be identified by non-invasive
bioluminescence measurement. Since solid tumors often contain hypoxic regions, we performed proof-of-principle
experiments testing whether this transgenic mouse model may be used as a universal platform for non-invasive imaging
analysis of spontaneous solid tumors.
Methods and Materials: ODD-luciferase transgenic mice were bred with MMTV-neu/beclin1+/2 mice. Upon injection of
luciferin, bioluminescent background of normal tissues in the transgenic mice and bioluminescent signals from
spontaneously mammary carcinomas were measured non-invasively with an IVIS Spectrum imaging station. Tumor volumes
were measured manually and the histology of tumor tissues was analyzed.
Conclusion: Our results show that spontaneous mammary tumors in ODD-luciferase transgenic mice generate substantial
bioluminescent signals, which are clearly discernable from background tissue luminescence. Moreover, we demonstrate a
strong quantitative correlation between the bioluminescent tumor contour and the volume of palpable tumors. We further
demonstrate that shrinkage of the volume of spontaneous tumors in response to chemotherapeutic treatment can be
determined quantitatively using this system. Finally, we show that the growth and development of spontaneous tumors can
be monitored longitudinally over several weeks. Thus, our results suggest that this model could potentially provide a
practical, reliable, and cost-effective non-invasive quantitative method for imaging spontaneous solid tumors in mice.
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Introduction
In human medicine, the detection and evaluation of tumors has
been an area of ongoing research for many years. The advent of
radiology as a diagnostic aid provided the first opportunity to
image internal tumors non-invasively, and progress over the past
three decades has resulted in a wide array of non-invasive, live-
tissue imaging options [1,2,3,4]. Examples of technology in this
rapidly expanding field include x-rays, ultrasonic imaging,
computed tomography, positron emission tomography, magnetic
resonance imaging, and nuclear scintigraphy. Many of these
imaging modalities can provide astonishingly detailed information
about a tumor, including size, shape, location, vasculature and
architecture; but most of the advanced techniques require
extensive training and experience to master, hence the existence
of board-certified radiologists within the medical profession.
In the laboratory, tumor imaging is a very different process. The
evolution of animal models for tumor research has resulted in the
predominant use of immunocompromised mice as hosts for
human xenograft and mouse allograft tumors, allowing researchers
to observe the growth and development of tumors in a ‘‘living test
tube.’’ While these models have made tremendous contributions to
our knowledge in the field of oncology, they also possess inherent
drawbacks which limit their usefulness [5,6]. First and foremost, it
has long been known that xenografts/allografts in mice do not
necessarily mimic the behavior they exhibit in their native
microenvironment [6,7,8]. Furthermore, the mice used in these
models are invariably immunocompromised to prevent rejection
of the xenograft. This condition alters the natural inhibitory
factors that cancer is subjected to in an otherwise immunocom-
petent host [6,7], allowing the xenograft to grow and even
metastasize. In the meantime, it also abolishes the pro-tumorigenic
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of tumors [9].
The recognition of the deficiencies of xenograft/allograft
models has led to a number of efforts to develop better mouse
tumor models, imaging systems, or both. With the recent advances
in genetic manipulation in mice, we are now able to selectively
knock out a tumor suppressor gene or overexpress an oncogene
which results in the spontaneous development of tumors in specific
tissues [6,10,11]. These models, of course, are not perfect, and
mouse tumors do not always behave similarly to their human
counterparts. In many instances, however, these spontaneous
murine tumor models can closely mirror human tumors with the
same genetic alterations. They are also excellent animal model
systems for determining the efficacy of anti-cancer therapeutics.
Although these genetically modified mice have provided us with
a superior model of spontaneous tumor development, the non-
invasive imaging of these tumors continues to pose a problem.
Imaging methods that are common in human oncology such as
ultrasonography, computed tomography, and magnetic resonance
imaging are often impractical for use in the laboratory due to
expense, safety, and the need for extensive technical expertise. The
most popular alternative has been the pursuit of bioluminescent or
fluorescent imaging techniques. In recent years, a number of
effective in vivo imaging models have been developed which
depend either upon the conditional expression of bioluminescent
reporter genes in concert with genes associated with a certain type
of tumor, or upon the use of fluorescent reporter molecules
directed towards specific cancer-associated cell proteins [12]. The
limitations of these models is that they are specific for only a single
type or subtype of cancer, and may not be broadly applied to
tumors of differing origins.
The core of developing any universally applicable tumor
imaging system is the differentiation of tumor cells from normal
tissue. At the physiological and metabolic levels there are
differences between cancerous tissue and normal tissue that, if
exploited, might provide a foundation for a more broadly
applicable tumor imaging system [13]. It has long been known
that despite their efforts to encourage angiogenesis, solid tumors
experience a certain degree of relative hypoxia when compared
with surrounding tissue [14,15,16]. Recently, a mouse model has
been developed in which regions of hypoxia may be imaged via
bioluminescent imaging [17]. In this model, Safran, et al. created
a transgenic mouse expressing the oxygen-dependent degradation
(ODD) domain of the Hypoxia Inducible Factor 1-a (HIF1-a)
gene fused to a luciferase bioluminescent reporter gene. The
HIF1-a gene is ubiquitously transcribed and translated, but
under normoxic conditions, the enzyme HIF prolyl hydroxylase
utilizes oxygen to hydroxylate the HIF ODD. The hydroxylated
ODD then recruits von Hipple-Lindau protein (pVHL), a
ubiquitin E3 ligase, leading to poly-ubiquitination of HIF1-a
and its subsequent degradation by the proteasome (Fig. 1A).
Conversely, under hypoxic conditions, lack of hydroxylation of
the ODD domain leads to the accumulation of HIF1-a
which acts as a transcriptional regulator for a number of
Figure 1. The effect of hypoxia on the HIF1-a degradation pathway and the scheme of the use of the ODD-Luciferase transgene for
bioluminescent imaging of spontaneous tumors. (A) HIF prolyl hydroxylase depends upon the substrate oxygen for hydroxylation of the ODD
domain in constitutively expressed HIF1-a protein in normoxic cells, ultimately leading to the degradation of HIF1-a via the ubiquitin-proteasome
pathway. The expression of the ODD-Luciferase transgene is identically regulated, leading to the accumulation of the ODD-Luciferase protein under
hypoxic conditions. (B) A schematic of the generation of mammary carcinoma-prone MMTV-neu/ODD-Luc/Beclin1 +/2 mice.
doi:10.1371/journal.pone.0018269.g001
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luciferase gene in mice, Safran, et al. developed an organism in
which luciferase is continuously transcribed and translated in all
cells, but is also be rapidly degraded under normoxic conditions.
Only under conditions of hypoxia does luciferase accumulate and
thus, by providing the substrate luciferin, regions of hypoxia
within these mice may be imaged with bioluminescent imaging
equipment.
We reasoned that solid tumors should be visible in ODD-
luciferase expressing mice due to the relative hypoxia experienced
by the tumor cells and hypothesized that the ODD-luciferase
transgenic model could serve as a universal platform for non-
invasive imaging of spontaneous solid tumors in mice. In this
report we conducted proof-of-principle studies by cross-breeding
transgenic mouse strains known to be predisposed to the
development of mammary gland tumors, the MMTV-neu [18]
and Beclin1 +/2 [19] mouse strains, with the ODD-luciferase mice
developed by Safran, et al. and subsequently characterized tumors
via bioluminescent monitoring. Our results show that mammary
tumors which develop in ODD-luciferase transgenic mice generate
substantial bioluminescent signals which are clearly discernable
from background tissue luminescence. Furthermore, we were able
to clearly track tumor growth and development longitudinally over
several weeks and were able to observe changes in tumor size in
response to chemotherapeutic treatment using this system. Thus,
our study provides experimental evidence supporting the principle
that this system may have potential for providing a universal
model for the non-invasive monitoring of spontaneously occurring
solid tumors in mice.
Results
Generation of ODD-luciferase transgenic mice
predisposed to mammary tumors and determination of
baseline organism-wide bioluminescent signals
associated with relative hypoxia
Early imaging data on ODD-Luc mice was obtained by Safran,
et al. in their description of this model [17]. Our initial objective
was to determine whether or not ODD-Luc transgenic mice
could be successfully interbred with other, non-ODD-Luc
transgenic mice to produce tumorigenic offspring capable of
being imaged with available bioluminescence detection tech-
nology. Specifically, we sought to exploit the principle of tumor
hypoxia as a means of monitoring tumor growth and response to
treatment in populations of wild-type and reduced-autophagy
mice. In our laboratory, we maintain a colony of mice
heterozygous for the haploinsufficient tumor suppressor gene
beclin1 [19], an autophagy-related gene commonly deleted in
h u m a nb r e a s tc a n c e r s .I na ne f f o r tt og e n e r a t em a m m a r y
tumors with beclin1 deletion, these mice were crossed with mice
bearing the MMTV (mouse mammary tumor virus promoter)-
neu transgene. Mutation of the human neu homologue, the her2
oncogene, is associated with the development of certain human
breast tumors [20,21,22,23]. The resulting MMTV-neu/beclin1+/
+ or +/2 mice were further crossed with ODD-luciferase mice.A s
expected, offspring develop mammary gland tumors with high
frequency (Fig. 1B, Table S1).
Prior to tumor development, we analyzed the baseline biolumi-
nescence in these tumorigenic mice. Figure 2 shows representa-
tive images of normal, tumor-free (as determined by post-imaging
necropsy), aged (18 month old) female mice. Images were
obtained of four views: dorsal, ventral, right lateral, and left
lateral (Fig. 2A), with the radiance for each image independently
scaled. Radiance is defined as photons/second/cm
2/steradian
and is considered the rate at which any given point in the image
generates photons. This rate is commonly used to compare
bioluminescent signals among different images taken in different
subjects or at different times, as it eliminates much of the
variability inherent in comparing raw photon ‘‘counts’’ for a
given area for a given image. In each view we observed a unique
signal distribution correlating to hypoxic area nearest the camera
lens. In the dorsal view, the kidneys generate a marked signal,
while in the ventral view, the abdominal fat pad and teats
generate relatively high background signals over the abdomen
and the thyroid generates a high intensity signal in the cervical
region. The lateral views each contain high intensity regions that
correlate with the respective kidney for that side, as well as signals
generated by the abdominal fat pad and the thyroid (Fig. 2A).
Later, the images were merged and forced to conform to a
common scale, (Fig. 2B), providing an accurate comparison of
relative hypoxia among views and revealing that the ventrum was
consistently the region with the highest background signal.
Finally, a variety of areas were observed to undergo transient
or shifting hypoxia, including the ears, tail, rump, feet, and scruff.
These areas can become transiently hypoxic in association with a
variety of factors, including changes in ambient temperature,
length of time under anesthesia, and sometimes the degree of
strength with which the mice were scruffed for restraint prior to
luciferin injection. However, it is clear that the bioluminescence
in these regions is low and transient when compared to the major
hypoxic regions of the kidneys, ventral abdomen, and thyroid
gland.
Analysis of spontaneously developing mammary tumors
in ODD-luc transgenic mice
Subcutaneous tumors began to appear on MMTV-neu/ODD-
luc/Beclin1 mutant mice at approximately 11 months of age,
regardless of beclin1 deletion status (Table S1). Initial imaging
candidates were selected and, when the tumors had reached
approximately 1 cm in diameter, the mice were subjected to
imaging and subsequently sacrificed. Necropsy was performed for
acquisition of gross and histological pathology data. As shown in
Figure 3A, the imaging sessions revealed obvious hypoxic
signatures that correlated with the observable tumor shape and
size. One subject (upper panels) bore a spherical mammary
carcinoma over the right shoulder generating a substantial
bioluminescent signal sufficient to suppress the normally
significant background signal generated by the kidneys. Another
subject (bottom panels) possessed a multilocular mammary
carcinoma located in the right ventral abdomen. Unlike the
subject in the upper panels, the tumor in this mouse generated a
signal similar in intensity to the right kidney, as evidenced by the
hypoxic zone noted just cranial to the tumor signal (Fig. 3A,
arrow). In both cases, tumors were clearly identifiable as areas of
relative hypoxia when compared to their surrounding, normoxic,
tissues.
In addition, we monitored palpable tumors over a six-week
period in several mice. Tumor contour was clearly visible on
bioluminescent imaging and changes in tumor size, shape, and
regions of hypoxia were observed. The imaging signature for
tumors consisted of a peripheral region areas of high signal
intensity surrounding a central region of low signal intensity. The
intensity of luciferase signals at the specific peripheral areas varied
among tumors and also varied within tumors at different time
points, but the distribution pattern and the collective contour or
outline of the high-intensity signaling always correlated with visible
tumor boundaries (Fig. 3B).
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carcinoma and the expression pattern of ODD-Luciferase
The heterogeneous nature of the signals observed in these
spontaneous tumors suggested that the tumors were also
heterogeneous and the different areas of the same tumor might
experience varying levels of hypoxia (Fig. 4A). In an effort to
correlate the observed signal patterns with tumor anatomy and
physiology, all imaged tumors were dissected during necropsy
following the conclusion of the imaging time course and were
submitted for histological processing and analysis. Histological
slides revealed that observed tumors were multilocular in nature,
each possessing multiple small discrete nodules (Fig. 4B, C). Each
nodule in a given tumor was made of layers of viable cells
surrounding a core of dead, necrotic tissue as evidenced by the
lack of DAPI-stained nuclei (Fig. 4A, C). The peripheral areas
were found to generate high- intensity bioluminescent signals.
When these peripheral tissue samples were subjected to
immunofluorescent staining with anti-luciferase primary anti-
body, the resulting fluorescein signal clearly illustrates an increase
in ODD-Luciferase expression in living cells as distance from the
available blood supply increases, with a precipitous drop in
ODD-Luciferase expression in the necrotic core of the nodule
(Fig. 4C). Furthermore, low signal intensity was observed in the
central nodules of these tumors (Figure 4A). This is likely
attributable to a combination of increased necrotic tissue, which
is incapable of generating a signal due to a lack of viable cells
containing the necessary ODD-luciferase enzyme, and to
decreased vascular supply, which limits the delivery of the
substrate luciferin to the tissues located in at the center region of a
tumor.
Figure 2. Evaluation of baseline bioluminescent signals in MMTV-neu/ODD-Luc/Beclin1 +/+ or +/2 mice. (A) Representative dorsal, ventral,
right lateral, and left lateral views of two female mice expressing the ODD-Luc and MMTV-neu transgenes. Each image is individually scaled for
radiance according to scale bars shown. (B) The images in panel (A) are adjusted to conform to the same radiance scale, showing the relative intensity
of signaling among all images.
doi:10.1371/journal.pone.0018269.g002
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radiance, correlates with tumor size
We initially expected to see a correlation between overall tumor
radiance and tumor size, but quickly realized that three factors
complicated this relationship. As previously noted, the tumors
being imaged in this study were all heterogeneous in nature, thus
resulting in non-uniform levels of ODD-Luciferase expression and
activity (Fig. 4A–B). Second, the phenomena of cycling hypoxia
[24,25] led us to believe that the radiance signals from any given
tumor could fluctuate over time. Finally, the existence of necrotic
tissue and restricted blood flow in the center of growing tumors
meant that the relative volume of hypoxic tissue is not
proportional to the total tumor volume. In fact, our observations
showed that there was remarkably little difference in tumor
radiance over nearly five weeks of observation, despite a significant
increase in tumor size (Fig. 5C). The variance observed in tumor
radiance was remarkably consistent both between tumors and also
between views, indicating that the changes were likely related to
the kinetics of luciferin injection and uptake, rather than to an
actual change in the hypoxic area of the tumors (Fig. 5C).
However, by utilizing the region of interest (ROI) tool in the
Living Image software suite, we could clearly identify the
perimeter of a tumor in a given view based on the peripheral
high-signal areas of bioluminescence and obtain a calculated area
from that view (Fig. 5A–B). When compared to manually obtained
measurements of area for each palpable tumor, the software-
obtained areas of tumor bioluminescent contour correlated closely
and provided an accurate determination of tumor cross-sectional
area (Fig. 5A, B, D). It is important to note that imaging position
had an effect on accuracy in determining tumor cross-sectional
area, and that the best values were obtained by imaging the mice
with the tumor facing directly towards the lens, as expected
(Fig. 5B, D).
Regression of tumors in response to drug treatment can
be tracked via bioluminescent imaging
We then performed a proof of principle study to determine if the
new spontaneous tumor model could be used for non-invasive in
vivo imaging of tumor size in response to chemotherapeutics. As
shown in Figure 6A, a mouse bearing a palpable tumor was
treated with doxorubicin and prednisone for a course of two
weeks. As witnessed in both the photographic and bioluminescent
images, the palpable tumor decreased in size during the drug
treatment. To gain a more quantitative measurement of tumor
regression, the tumor dimensions were obtained manually by the
use of calipers while the measurement of the bioluminescent
region of interest (red circles) was obtained through the Living
Image software from the ventral and lateral views. The tumor
volume was then calculated based on these measurements as
described in material and methods. As shown in Figure 6B, the
regression of the tumor volume as measured by bioluminescence
signal contour correlates with that determined manually. These
results indicate that this imaging system can be used as a technique
to track the regression of spontaneous tumors during drug
treatment.
Nascent impalpable mammary tumors are detectable
and may be tracked longitudinally in MMTV-neu/ODD-
Luc/Beclin1 +/+ or +/2 mice via bioluminescent imaging
In the early phase of this study, only mice bearing palpable
tumors were imaged. This work established that tumors could be
successfully monitored over time for changes in size, shape, and
hypoxic regions. Following this finding, we scanned large numbers
of mice on a weekly basis to determine at what stage tumors could
be imaged. Existing literature has shown that bioluminescent
xenografts can be imaged to the single-cell level in nude mice [26]
but our system relies upon being able to separate the signal of a
hypoxic tumor from the background bioluminescence previously
described. We found that this system was capable of detecting
tumors in mice at least several weeks before they were palpable.
Figure 7 illustrates the continuous tracking of bioluminescent
signal in the region of the left cranial mammary gland over a
period of 67 days. As expected, the thyroid region and the
extremities show hypoxic signals. Starting from day 7, a hypoxic
signal (indicated by an arrow, Figure 7) is noticeable and it persists
throughout the whole experimental period. The tumor corre-
sponding to the hypoxic signal only became palpable on day 48.
These data indicate that this imaging model may serve as a
sensitive technique for the detection of the development of very
small subcutaneous tumors in haired mice.
Discussion
Xenografts have served as a valuable model system for cancer
biology for many years, but they are subject to significant
limitations. While they provide relatively easy imaging of cancer
growth, they place the tumor in a non-native, immunocompro-
mised environment that fails to recreate its original in situ milieu.
The advent of genetic manipulation has led to the development of
improved mouse models of cancer in which tumors appear
spontaneously and develop naturally in their native environment.
These genetically driven models, while superior in providing a
Figure 3. Bioluminescent images of spontaneous tumors. (A)
Photographic and luminescent images of two female mice, one bearing
a subcutaneous tumor above the right scapula (top panels) and another
bearing a subcutaneous tumor on the right abdomen/inguinal region
(bottom panels) with photographs of the dissected tumor masses.
White circles denote the approximate boundaries of the tumor masses
in this view. Note the underlying strong signal generated by the right
kidney (arrow) intensified due to decreased subcutaneous and adipose
tissue mass. (B) Longitudinal tracking of subcutaneous tumor develop-
ment in a female mouse.
doi:10.1371/journal.pone.0018269.g003
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behavior, are difficult to image in the laboratory using existing
techniques and technology. Here we report a system that could be
used as a potentially universal platform for the non-invasive
imaging of spontaneously-occurring, solid tumors. Using the ODD-
luciferase transgenic mouse in concert with tumorigenic mouse
mutants, we have analyzed base-line background signals from non-
tumor-bearing mice, imaged a series of spontaneously developing
mammary tumors over time, and conducted a proof-of principle
study showing the feasibility of this model.
Our results indicate that bioluminescent imaging of tumor-
bearing ODD-luciferase mice can detect mammary tumors. Further-
more, by using the contour of the luminescent signal, we can
accurately track tumor growth over time. In particular, this
approach can track shrinkage of tumor in vivo in response to
cancer chemotherapy. Finally, we have shown that this model is
sensitive enough to allow detection of tumors many weeks before
they become physically palpable. Taken together, these proof-of-
principle findings support that this imaging model is suitable for the
non-invasive monitoring of spontaneous mammary tumors in mice.
One important conclusion from our study is that the
bioluminescent signal contour rather than the bioluminescent
radiance correlates with tumor size. The bioluminescent signal
intensity is determined by two major factors, the accumulation of
luciferase and the availability of the substrate luciferin. Luciferase
accumulates in living but hypoxic cells. Lack of vascularization in
mammary tumors on the one hand creates the hypoxic cellular
environment which promotes the accumulation of the ODD-
luciferase fusion protein; on the other hand, it leads to necrotic cell
death at the center of the tumors (Figure 4C). As the tumor volume
increases, so does the tumor necrotic center. Consequently the net
accumulation of luciferase does not correlate with the tumor
volume (Figure 5C). In addition, lack of vascularization greatly
reduces the availability of the substrate, luciferin, in the center
region of a tumor. This is likely another major reason why the
center region of a tumor has low level of bioluminescence intensity
and the bioluminescent radiance does not correlate with tumor
volume. In contrast, the cells in the peripheral regions of the
tumors that undergo normoxia/hypoxia transition (Figure 4) are
alive. They experience certain levels of hypoxic stress and have
access to the substrate luciferin. Thus these cells consistently
exhibit higher bioluminescent signals, forming a bioluminescent
contour that reflects the actual size of the tumor.
Although this study was limited to the evaluation of mammary
tumors, any other tumor that experiences hypoxia should be visible
through the use of this system. Thus, this model has the potential for
widespread utilization, as it relies upon a characteristic innate to all
solid tumors, the presence of relative hypoxia due to poor vascular
Figure 4. Histological analysis of mammary carcinomas and the expression of ODD-luciferase. (A) Representative subcutaneous tumors
on the left cervical and right abdominal aspects of a female MMTV-neu/ODD-Luc/Beclin1 +/2 mouse. White circles denote approximate boundaries of
tumor masses. (B) Hematoxylin and Eosin stained paraffin-embedded tumor tissue sections at 2006 (top panels) and 10006 (bottom panels)
magnification. White arrows denote the presence of mitotic cells in the viable peripheral tumor tissue. (C) Immunofluorescent analysis of two tumor
tissue samples with anti-luciferase antibody. Left panels show immunofluorescent signaling representing the presence of luciferase. Center panels are
DAPI stained representing the nuclei of viable cells. Right panels are merged fluorescein/DAPI images. NC: necrotic core (region without DAPI
staining). Histograms illustrate the fluorescein signal intensity in relation to the distance from local vasculature.
doi:10.1371/journal.pone.0018269.g004
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invasive imaging of a variety of spontaneously occurring tumors is
available which will facilitate our ability to gather data in genetically
driven mouse cancer models. Moreover, the capability of
monitoring the development of the same spontaneous tumors over
time makes this model particularly appealing for the in vivo
evaluation of the efficacy of novel cancer chemotherapeutics.
Drawbacks to this model certainly exist, the key one being the
presence of background signals as noted on Figure 2. It is clear
that hypoxia is intrinsic in some normal tissues, such as the kidneys
and thyroid, which may make the observation or localization of
tumors arising near or from these tissues impractical. Moreover,
the generally high background observed in the images of the
ventral abdomen indicates that tumors located on the dorsal
surface of the animal may be more readily imaged than those
located elsewhere. Furthermore, our model is also dedicated to the
exploration of the mammary carcinoma, an exclusively subcuta-
neous tumor, and it is difficult to accurately predict what attempts
to image deeper tumors may find. Deep tumors likely will emit
signals strong enough to be detected, but the distortion of the
signals due to travel through heterogeneous tissues will add an
additional level of complexity to data interpretation and analysis.
Further work will be needed to experimentally determine which
types of solid tumors are amenable to this imaging model.
Materials and Methods
Ethics Statement
The study involved mice and the protocol had been approved
by University of Medicine and Dentistry of New Jersey-Robert
Figure 5. Correlation of tumor bioluminescence signal and tumor volume. (A) Manually calculated tumor area compared to computer-
obtained tumor bioluminescent contour by view (left lateral, or LL, versus dorsal, or D) of subcutaneous abdominal tumor in a female MMTV-neu/
ODD-Luc/Beclin1 +/2 mouse over time. (B) Manually calculated tumor area compared to computer-obtained tumor bioluminescent contour by view
(right lateral, or RL, versus dorsal, or D) of subcutaneous cervical tumor in the same female MMTV-neu/ODD-Luc/Beclin1 +/2 mouse over time. (C)
Computer-obtained radiance (photons/second/cm
2/steradian) in both cervical and abdominal tumors over time, by view (right or left lateral and
dorsal). (D). Statistical analyses of results from (A) and (B) to determine the correlation between the tumor size measured manually and by
bioluminescent signal contour. Pearson coefficients and P values are shown.
doi:10.1371/journal.pone.0018269.g005
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Use Committee (IACUC). Approval ID: I07-038-3. All mice were
housed under standard conditions per IACUC and university
vivarium protocols in a barrier facility.
Transgenic Mouse Generation
FVB/N-Tg (MMTV-neu)202Mul/J (referred to herein as
MMTV-neu) mice, stock number 02376 were obtained from
Jackson Laboratories (Bar Harbor, ME) at eight weeks of age
and bred with C57BL/6 background Beclin1 wild-type (+/+) and
heterozygous (+/2) mice from a sustained laboratory colony.
FVB.129S6-Gt(ROSA)26Sor
tm1(HIF1A/luc)Kael/J (referred to herein as
ODD-Luc) mice were obtained from Jackson Laboratories at eight
weeks of age and cross bred with Beclin1+/+,MMTV-neu and
Beclin1+/2,MMTV-neu mice to generate Beclin1+/+,MMTV-neu,
ODD-Luc and Beclin1+/2,MMTV-neu,ODD-Luc offspring for im-
aging.
Mouse Genotyping
Mice were genotyped via tail tip amputation and digestion for
DNA extraction utilizing the Qiagen DNeasy assay (Alameda, CA).
Following DNA extraction, DNA samples were subjected to
polymerase chain reactions with times, temperatures, and DNA
primers tailored per existing protocols for the beclin1 [19], MMTV-
neu, and ODD-Lucgenes (available from Jackson Laboratories, www.
jaxmice.jax.org). PCR products were loaded into wells in gels
consisting of 1.5% agarose, suspended in TSA buffer, and subjected
to electrophoresis. The gels were imaged on a UVP Gel
Documentation System (Upland, CA) and compared to known
controls to determine genotype with respect to genes of interest.
Mouse Imaging
Mice were selected for imaging and placed in the IVIS
induction chamber three at a time and subjected to inhalational
isoflurane anesthesia (Abbott, Abbott Park, IL) at 3% with 1 L/
min flow of oxygen. Following induction, mice were individually
removed from the induction chamber and given an intraperitoneal
injection of 50 mg/kg luciferin (Promega, Madison, WI) suspend-
ed in sterile phosphate-buffered saline (Invitrogen, Carlsbad, CA).
After a ten minute incubation period, the mice were placed on the
heated imaging platform of the IVIS Spectrum imaging station
(Caliper, Hopkinton, MA) with inhalational isoflurane anesthesia
at 1.5% with 1 L/min flow of oxygen during the imaging
procedure. White light and luciferase activity images were
obtained at 30 second intervals for five minutes. Following
imaging, mice were removed from the imaging stage and allowed
to recover from anesthesia in a heated cage. Mice were observed
for normal behavior prior to being returned to their original
housing. Images were subjected to interpretation on Living Image
software (Caliper) for evaluation and quantification.
Immunofluorescence
Paraffin-embedded, slide-mounted tissue sections were depar-
affinized and hydrated per standard protocol. Following rehydra-
tion, slides were placed in 10 mM Sodium Citrate buffer and
placed in a boiling water bath for twenty minutes. Slides were
cooled and washing, and tissue sections were blocked for one hour
with 10% goat serum in phosphate-buffered saline/Triton X-100
(PBST) in a humid, light-tight box at room temperature. Following
blocking, tissue sections were exposed to a 1:50 dilution of primary
anti-firefly luciferase antibody #G7451 (Promega) in PBST
overnight. After washing, secondary donkey-anti-goat antibody
#SC-2020 (Santa Cruz Biotech, Santa Cruz, CA) was applied at a
1:100 ratio in PBST with a 1:10000 dilution of DAPI stain
(Invitrogen) for one hour. Slides were then mounted in vectashield
medium (Vector Labs, Burlingame, CA) and immediately
evaluated for fluorescence on a Zeiss (Thornwood, NY) Axioplan
2 microscope with an EXFO X-cite 120 Fluorescence Imaging
System (Quebec, Canada). Digital images were obtained and
Figure 6. Tracking the regression of spontaneous tumors during drug treatment. (A) Photographic and bioluminescent images of a
shrinking palpable tumor over a 14- day drug treatment as described in materials and methods. White arrow in photographic view indicates location
of tumor. The red circles in bioluminescent view indicate region of interest. (B) Relative tumor volume expressed as a percent of initial tumor from
manually measuring tumor volume (&) vs. software calculated (ROI) tumor volume (e) based on bioluminescence signal contour over the course of
drug treatment as described in materials and methods. Pearson coefficient (r) and P value are shown.
doi:10.1371/journal.pone.0018269.g006
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Histograms were generated using ImageJ software, freely obtained
from the National Institutes of Health at http://rsp.info.nih.gov/ij.
Mouse Necropsy and Histology
Mice were humanely euthanized via cervical dislocation.
Immediately following euthanasia, tumors were dissected out
and photographs were taken of the tumor in situ. Tumors were
then removed, measured, weighed, photographed and sectioned if
necessary, and portions were placed in Millonig’s 10% buffered
formalin (Surgipath, Richmond, IL) for 24 hours prior to being
placed in 70% ethanol. Remaining tissue was snap-frozen and
stored in liquid nitrogen for future use. Following tumor removal
and preservation, a complete necropsy was performed and any
gross pathology was noted. Formalinized/ethanol-preserved tissue
was submitted to Tissue Analytical Services at the Cancer Institute
of New Jersey for paraffin-embedding, sectioning, selective
hematoxylin and eosin (H&E) staining, and mounting on glass
slides. H&E stained slides were imaged on a Zeiss Axioplan 2
microscope with a Zeiss HAL 100 light source. Digital images
were obtained via a Sony Cybershot DSC-HX1 camera mounted
with a Micron Optics (Cedar Knolls, NJ) MM99-HX1 microscope
adapter.
Tumor area, tumor volume, radiance calculation, and
statistical analysis
Manual measurements of tumor area were obtained by
measuring the widest and narrowest axes of the tumor with
calipers and then calculating the area of an oval by the following
equation: A=p*a*b, where a is the radius of the short axis and b is
the radius of the long axis. Computer-obtained cross-sectional
tumor areas were obtained with Living Image software (Caliper)
through the use of the automatic region of interest (ROI) function.
Images were forced to conform to predetermined scales of
radiance, and ROIs were automatically generated around tumors
with a threshold of 25%, a lower limit of 1, and a minimum size of
20. ROIs were then evaluated for total area and total radiance via
the Living Image software, and results were exported to Microsoft
Office 2007 (Microsoft, Redmond, WA) for analysis and graphing.
Tumor volume manual measurements were obtained by
measuring the widest and narrowest axes of the tumor with
calipers from two different views (right lateral and ventral) and
then calculating the volume of an ellipsoid by the following
equation: V=4/3 * p * a * b * c, where a is the radius of the x axis,
b is the radius of the y axis, and c is the radius of the z axis.
Computer-obtained tumor volume was obtained with the Living
Image software through the use of the free-style region of interest
function. A region of interest was manually drawn around the
bioluminescence of the tumor from two different views (right
lateral and ventral). Software generated x, y, and z axis radii from
the region of interest were used for the volume of an ellipsoid
equation.
The size of a palpable tumor in each mouse was measured over
the experimental period either manually or by bioluminescence
detection. The Pearson correlation coefficient (r) was used to
assess the correlation between results obtained by the two
measurements. All p values are reported as testing the null
hypothesis of zero correlation (r=).
Tumor treatment
Treatment of tumor-bearing animals was conducted as follows:
Doxorubicin (4 mg/kg, Sigma) was given every other day for 2
weeks by intraperitoneal injection. In addition, prednisone
(0.2 mg/kg, Sigma) was given orally daily for 2 weeks by gavage.
Mice were subjected to imaging every other day, starting on day 1
and before each new doxorubicin injection.
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